Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico
Background and Objective. Hematopoietic stem cell transplantation (HSCT) in developing countries is cost‐limited. Our primary goal was to determine the cost structure for the HSCT program model developed over the last decade at our public university hospital and to assess its clinical outcomes. Mate...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2015-04, Vol.20 (4), p.386-392 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 392 |
|---|---|
| container_issue | 4 |
| container_start_page | 386 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 20 |
| creator | Jaime‐Pérez, José Carlos Heredia‐Salazar, Alberto Carlos Cantú‐Rodríguez, Olga G. Gutiérrez‐Aguirre, Homero Villarreal‐Villarreal, César Daniel Mancías‐Guerra, Consuelo Herrera‐Garza, José Luís Gómez‐Almaguer, David |
| description | Background and Objective.
Hematopoietic stem cell transplantation (HSCT) in developing countries is cost‐limited. Our primary goal was to determine the cost structure for the HSCT program model developed over the last decade at our public university hospital and to assess its clinical outcomes.
Materials and Methods.
Adults and children receiving an allogeneic hematopoietic stem cell transplant from January 2010 to February 2011 at our hematology regional reference center were included. Laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization costs were scrutinized to calculate the total cost for each patient and the median cost for the procedure. Data regarding clinical evolution were incorporated into the analysis. Physician fees are not charged at the institution and therefore were not included.
Results.
Fifty patients were evaluated over a 1‐year period. The total estimated cost for an allogeneic HSCT was $12,504. The two most expensive diseases to allograft were non‐Hodgkin lymphoma ($11,760 ± $2,236) for the malignant group and thalassemia ($12,915 ± $5,170) for the nonmalignant group. Acute lymphoblastic leukemia ($11,053 ± 2,817) and acute myeloblastic leukemia ($10,251 ± $1,538) were the most frequent indications for HSCT, with 11 cases each. Median out‐of‐pocket expenses were $1,605, and 1‐year follow‐up costs amounted to $1,640, adding up to a total cost of $15,749 for the first year. The most expensive components were drugs and laboratory tests.
Conclusion.
Applying the cost structure described, HSCT is an affordable option for hematological patients living in a developing country.
The costs of laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization of patients receiving an allogeneic hematopoietic stem cell transplantation (HSCT) were scrutinized to calculate the total cost for each patient and the median cost for the procedure and to assess its clinical outcomes. The results show that HSCT is an affordable option for hematological patients living in a developing country. |
| doi_str_mv | 10.1634/theoncologist.2014-0218 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4391759</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1732821494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4346-16cdbdd1c2ee90fb134b2cf8d3085c0df581c666782d62403b11c1f464e246143</originalsourceid><addsrcrecordid>eNqNkdtu1DAQhiMEomXhFcCX3KT4FCdBAgmFcpBKF4lF4s7yOpNdI8cOtlO6L8Bz42hLRa_gakaab_45_EXxjOAzIhh_kfbgnfbW70xMZxQTXmJKmnvFKal4W_IWf7ufc9ywsiZVe1I8ivE7xjll9GFxQquaZxl2WvzqfEzoSwqzTnMApFyPOmuc0cqi9Zy0HwH5AanMwIg6sBZtgnJxssollYx36HPwu6BGZFzG3sIVWD8Zt0Odn10Kh5doswd0fj1BMOA0LNylD_kElUd_gmuj_ePiwaBshCc3cVV8fXe-6T6UF-v3H7s3F6XmjIuSCN1v-55oCtDiYUsY31I9ND3DTaVxP1QN0UKIuqG9oByzLSGaDFxwoFwQzlbF66PuNG9H6DXkBZWVUzCjCgfplZF3K87s5c5fSc5aUufvrYrnNwLB_5ghJjmaqPNXlAM_R0lqRhtKeMv_jYqaClzhZlGtj6gOPsYAw-1GBMvFcHnHcLkYLhfDc-fTvw-67fvjcAZeHYGfxsLhf3Xl-rJbY9YI9hs8a8HO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1672605089</pqid></control><display><type>article</type><title>Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico</title><source>Oxford Journals Open Access Collection</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Jaime‐Pérez, José Carlos ; Heredia‐Salazar, Alberto Carlos ; Cantú‐Rodríguez, Olga G. ; Gutiérrez‐Aguirre, Homero ; Villarreal‐Villarreal, César Daniel ; Mancías‐Guerra, Consuelo ; Herrera‐Garza, José Luís ; Gómez‐Almaguer, David</creator><creatorcontrib>Jaime‐Pérez, José Carlos ; Heredia‐Salazar, Alberto Carlos ; Cantú‐Rodríguez, Olga G. ; Gutiérrez‐Aguirre, Homero ; Villarreal‐Villarreal, César Daniel ; Mancías‐Guerra, Consuelo ; Herrera‐Garza, José Luís ; Gómez‐Almaguer, David</creatorcontrib><description>Background and Objective.
Hematopoietic stem cell transplantation (HSCT) in developing countries is cost‐limited. Our primary goal was to determine the cost structure for the HSCT program model developed over the last decade at our public university hospital and to assess its clinical outcomes.
Materials and Methods.
Adults and children receiving an allogeneic hematopoietic stem cell transplant from January 2010 to February 2011 at our hematology regional reference center were included. Laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization costs were scrutinized to calculate the total cost for each patient and the median cost for the procedure. Data regarding clinical evolution were incorporated into the analysis. Physician fees are not charged at the institution and therefore were not included.
Results.
Fifty patients were evaluated over a 1‐year period. The total estimated cost for an allogeneic HSCT was $12,504. The two most expensive diseases to allograft were non‐Hodgkin lymphoma ($11,760 ± $2,236) for the malignant group and thalassemia ($12,915 ± $5,170) for the nonmalignant group. Acute lymphoblastic leukemia ($11,053 ± 2,817) and acute myeloblastic leukemia ($10,251 ± $1,538) were the most frequent indications for HSCT, with 11 cases each. Median out‐of‐pocket expenses were $1,605, and 1‐year follow‐up costs amounted to $1,640, adding up to a total cost of $15,749 for the first year. The most expensive components were drugs and laboratory tests.
Conclusion.
Applying the cost structure described, HSCT is an affordable option for hematological patients living in a developing country.
The costs of laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization of patients receiving an allogeneic hematopoietic stem cell transplantation (HSCT) were scrutinized to calculate the total cost for each patient and the median cost for the procedure and to assess its clinical outcomes. The results show that HSCT is an affordable option for hematological patients living in a developing country.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1634/theoncologist.2014-0218</identifier><identifier>PMID: 25746343</identifier><language>eng</language><publisher>Durham, NC, USA: AlphaMed Press</publisher><subject>Costs and Cost Analysis ; Developing Countries ; Female ; Global Health and Cancer ; Hematopoietic stem cell transplant ; Hematopoietic Stem Cell Transplantation - economics ; HSCT cost containment ; HSCT cost structure ; HSCT costs ; HSCT in developing countries ; Humans ; Leukemia, Myeloid, Acute - therapy ; Lymphoma, Non-Hodgkin - therapy ; Male ; Mexico ; Out‐of‐pocket expenses ; Thalassemia - therapy ; Transplantation, Homologous - economics ; Treatment Outcome</subject><ispartof>The oncologist (Dayton, Ohio), 2015-04, Vol.20 (4), p.386-392</ispartof><rights>2015 AlphaMed Press</rights><rights>AlphaMed Press.</rights><rights>AlphaMed Press 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4346-16cdbdd1c2ee90fb134b2cf8d3085c0df581c666782d62403b11c1f464e246143</citedby><cites>FETCH-LOGICAL-c4346-16cdbdd1c2ee90fb134b2cf8d3085c0df581c666782d62403b11c1f464e246143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391759/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391759/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,27901,27902,45550,45551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25746343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jaime‐Pérez, José Carlos</creatorcontrib><creatorcontrib>Heredia‐Salazar, Alberto Carlos</creatorcontrib><creatorcontrib>Cantú‐Rodríguez, Olga G.</creatorcontrib><creatorcontrib>Gutiérrez‐Aguirre, Homero</creatorcontrib><creatorcontrib>Villarreal‐Villarreal, César Daniel</creatorcontrib><creatorcontrib>Mancías‐Guerra, Consuelo</creatorcontrib><creatorcontrib>Herrera‐Garza, José Luís</creatorcontrib><creatorcontrib>Gómez‐Almaguer, David</creatorcontrib><title>Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Background and Objective.
Hematopoietic stem cell transplantation (HSCT) in developing countries is cost‐limited. Our primary goal was to determine the cost structure for the HSCT program model developed over the last decade at our public university hospital and to assess its clinical outcomes.
Materials and Methods.
Adults and children receiving an allogeneic hematopoietic stem cell transplant from January 2010 to February 2011 at our hematology regional reference center were included. Laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization costs were scrutinized to calculate the total cost for each patient and the median cost for the procedure. Data regarding clinical evolution were incorporated into the analysis. Physician fees are not charged at the institution and therefore were not included.
Results.
Fifty patients were evaluated over a 1‐year period. The total estimated cost for an allogeneic HSCT was $12,504. The two most expensive diseases to allograft were non‐Hodgkin lymphoma ($11,760 ± $2,236) for the malignant group and thalassemia ($12,915 ± $5,170) for the nonmalignant group. Acute lymphoblastic leukemia ($11,053 ± 2,817) and acute myeloblastic leukemia ($10,251 ± $1,538) were the most frequent indications for HSCT, with 11 cases each. Median out‐of‐pocket expenses were $1,605, and 1‐year follow‐up costs amounted to $1,640, adding up to a total cost of $15,749 for the first year. The most expensive components were drugs and laboratory tests.
Conclusion.
Applying the cost structure described, HSCT is an affordable option for hematological patients living in a developing country.
The costs of laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization of patients receiving an allogeneic hematopoietic stem cell transplantation (HSCT) were scrutinized to calculate the total cost for each patient and the median cost for the procedure and to assess its clinical outcomes. The results show that HSCT is an affordable option for hematological patients living in a developing country.</description><subject>Costs and Cost Analysis</subject><subject>Developing Countries</subject><subject>Female</subject><subject>Global Health and Cancer</subject><subject>Hematopoietic stem cell transplant</subject><subject>Hematopoietic Stem Cell Transplantation - economics</subject><subject>HSCT cost containment</subject><subject>HSCT cost structure</subject><subject>HSCT costs</subject><subject>HSCT in developing countries</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>Male</subject><subject>Mexico</subject><subject>Out‐of‐pocket expenses</subject><subject>Thalassemia - therapy</subject><subject>Transplantation, Homologous - economics</subject><subject>Treatment Outcome</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkdtu1DAQhiMEomXhFcCX3KT4FCdBAgmFcpBKF4lF4s7yOpNdI8cOtlO6L8Bz42hLRa_gakaab_45_EXxjOAzIhh_kfbgnfbW70xMZxQTXmJKmnvFKal4W_IWf7ufc9ywsiZVe1I8ivE7xjll9GFxQquaZxl2WvzqfEzoSwqzTnMApFyPOmuc0cqi9Zy0HwH5AanMwIg6sBZtgnJxssollYx36HPwu6BGZFzG3sIVWD8Zt0Odn10Kh5doswd0fj1BMOA0LNylD_kElUd_gmuj_ePiwaBshCc3cVV8fXe-6T6UF-v3H7s3F6XmjIuSCN1v-55oCtDiYUsY31I9ND3DTaVxP1QN0UKIuqG9oByzLSGaDFxwoFwQzlbF66PuNG9H6DXkBZWVUzCjCgfplZF3K87s5c5fSc5aUufvrYrnNwLB_5ghJjmaqPNXlAM_R0lqRhtKeMv_jYqaClzhZlGtj6gOPsYAw-1GBMvFcHnHcLkYLhfDc-fTvw-67fvjcAZeHYGfxsLhf3Xl-rJbY9YI9hs8a8HO</recordid><startdate>201504</startdate><enddate>201504</enddate><creator>Jaime‐Pérez, José Carlos</creator><creator>Heredia‐Salazar, Alberto Carlos</creator><creator>Cantú‐Rodríguez, Olga G.</creator><creator>Gutiérrez‐Aguirre, Homero</creator><creator>Villarreal‐Villarreal, César Daniel</creator><creator>Mancías‐Guerra, Consuelo</creator><creator>Herrera‐Garza, José Luís</creator><creator>Gómez‐Almaguer, David</creator><general>AlphaMed Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TO</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>201504</creationdate><title>Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico</title><author>Jaime‐Pérez, José Carlos ; Heredia‐Salazar, Alberto Carlos ; Cantú‐Rodríguez, Olga G. ; Gutiérrez‐Aguirre, Homero ; Villarreal‐Villarreal, César Daniel ; Mancías‐Guerra, Consuelo ; Herrera‐Garza, José Luís ; Gómez‐Almaguer, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4346-16cdbdd1c2ee90fb134b2cf8d3085c0df581c666782d62403b11c1f464e246143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Costs and Cost Analysis</topic><topic>Developing Countries</topic><topic>Female</topic><topic>Global Health and Cancer</topic><topic>Hematopoietic stem cell transplant</topic><topic>Hematopoietic Stem Cell Transplantation - economics</topic><topic>HSCT cost containment</topic><topic>HSCT cost structure</topic><topic>HSCT costs</topic><topic>HSCT in developing countries</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>Male</topic><topic>Mexico</topic><topic>Out‐of‐pocket expenses</topic><topic>Thalassemia - therapy</topic><topic>Transplantation, Homologous - economics</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jaime‐Pérez, José Carlos</creatorcontrib><creatorcontrib>Heredia‐Salazar, Alberto Carlos</creatorcontrib><creatorcontrib>Cantú‐Rodríguez, Olga G.</creatorcontrib><creatorcontrib>Gutiérrez‐Aguirre, Homero</creatorcontrib><creatorcontrib>Villarreal‐Villarreal, César Daniel</creatorcontrib><creatorcontrib>Mancías‐Guerra, Consuelo</creatorcontrib><creatorcontrib>Herrera‐Garza, José Luís</creatorcontrib><creatorcontrib>Gómez‐Almaguer, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jaime‐Pérez, José Carlos</au><au>Heredia‐Salazar, Alberto Carlos</au><au>Cantú‐Rodríguez, Olga G.</au><au>Gutiérrez‐Aguirre, Homero</au><au>Villarreal‐Villarreal, César Daniel</au><au>Mancías‐Guerra, Consuelo</au><au>Herrera‐Garza, José Luís</au><au>Gómez‐Almaguer, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2015-04</date><risdate>2015</risdate><volume>20</volume><issue>4</issue><spage>386</spage><epage>392</epage><pages>386-392</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Background and Objective.
Hematopoietic stem cell transplantation (HSCT) in developing countries is cost‐limited. Our primary goal was to determine the cost structure for the HSCT program model developed over the last decade at our public university hospital and to assess its clinical outcomes.
Materials and Methods.
Adults and children receiving an allogeneic hematopoietic stem cell transplant from January 2010 to February 2011 at our hematology regional reference center were included. Laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization costs were scrutinized to calculate the total cost for each patient and the median cost for the procedure. Data regarding clinical evolution were incorporated into the analysis. Physician fees are not charged at the institution and therefore were not included.
Results.
Fifty patients were evaluated over a 1‐year period. The total estimated cost for an allogeneic HSCT was $12,504. The two most expensive diseases to allograft were non‐Hodgkin lymphoma ($11,760 ± $2,236) for the malignant group and thalassemia ($12,915 ± $5,170) for the nonmalignant group. Acute lymphoblastic leukemia ($11,053 ± 2,817) and acute myeloblastic leukemia ($10,251 ± $1,538) were the most frequent indications for HSCT, with 11 cases each. Median out‐of‐pocket expenses were $1,605, and 1‐year follow‐up costs amounted to $1,640, adding up to a total cost of $15,749 for the first year. The most expensive components were drugs and laboratory tests.
Conclusion.
Applying the cost structure described, HSCT is an affordable option for hematological patients living in a developing country.
The costs of laboratory tests, medical procedures, chemotherapy drugs, other drugs, and hospitalization of patients receiving an allogeneic hematopoietic stem cell transplantation (HSCT) were scrutinized to calculate the total cost for each patient and the median cost for the procedure and to assess its clinical outcomes. The results show that HSCT is an affordable option for hematological patients living in a developing country.</abstract><cop>Durham, NC, USA</cop><pub>AlphaMed Press</pub><pmid>25746343</pmid><doi>10.1634/theoncologist.2014-0218</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2015-04, Vol.20 (4), p.386-392 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4391759 |
| source | Oxford Journals Open Access Collection; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Costs and Cost Analysis Developing Countries Female Global Health and Cancer Hematopoietic stem cell transplant Hematopoietic Stem Cell Transplantation - economics HSCT cost containment HSCT cost structure HSCT costs HSCT in developing countries Humans Leukemia, Myeloid, Acute - therapy Lymphoma, Non-Hodgkin - therapy Male Mexico Out‐of‐pocket expenses Thalassemia - therapy Transplantation, Homologous - economics Treatment Outcome |
| title | Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A15%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20Structure%20and%20Clinical%20Outcome%20of%20a%20Stem%20Cell%20Transplantation%20Program%20in%20a%20Developing%20Country:%20The%20Experience%20in%20Northeast%20Mexico&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Jaime%E2%80%90P%C3%A9rez,%20Jos%C3%A9%20Carlos&rft.date=2015-04&rft.volume=20&rft.issue=4&rft.spage=386&rft.epage=392&rft.pages=386-392&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1634/theoncologist.2014-0218&rft_dat=%3Cproquest_pubme%3E1732821494%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1672605089&rft_id=info:pmid/25746343&rfr_iscdi=true |